Show simple item record

dc.contributor.authorCojocaru, E
dc.contributor.authorParkinson, CA
dc.contributor.authorBrenton, JD
dc.date.accessioned2018-10-09T09:35:43Z
dc.date.available2018-10-09T09:35:43Z
dc.date.issued2018-08
dc.identifier.issn1433-2981
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/283246
dc.description.abstractOvarian cancer is a heterogeneous group of cancers that differ by cell of origin and genomic features. High-grade serous ovarian cancer (HGSOC) is the commonest histiotype and is characterized by extreme genomic complexity and dysregulation of DNA damage repair pathways, particularly homologous recombination deficiency. New insights from molecular profiling into homologous recombination deficiency now offers the credible possibility of personalizing treatment choices for women with HGSOC using poly(ADP-ribose) polymerase inhibitor (PARP) therapy. Although the presence of tumour infiltrating lymphocytes (TILs) in the microenvironment is associated with improved survival in HGSOC, the role of anti-angiogenic and immune checkpoint inhibitor therapy remains unclear. PARP inhibition combined with immunotherapy is an exciting combination strategy for future therapeutic development for women with advanced HGSOC.
dc.languageeng
dc.publisherElsevier
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectGenomics
dc.subjectPARP inhibitors
dc.subjecthigh-grade serous ovarian cancer
dc.titlePersonalising Treatment for High-Grade Serous Ovarian Carcinoma.
dc.typeArticle
prism.endingPage524
prism.issueIdentifier8
prism.publicationDate2018
prism.publicationNameClinical Oncology
prism.startingPage515
prism.volume30
dc.identifier.doi10.17863/CAM.30611
dcterms.dateAccepted2018-05-22
rioxxterms.versionofrecord10.1016/j.clon.2018.05.008
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2018-08
dc.contributor.orcidBrenton, James [0000-0002-5738-6683]
dc.identifier.eissn1433-2981
rioxxterms.typeJournal Article/Review
cam.issuedOnline2018-06-19
rioxxterms.freetoread.startdate2019-06-19


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International